Stanley B Cohen

Summary

Affiliation: The University of Texas Southwestern Medical Center at Dallas
Country: USA

Publications

  1. doi request reprint Rheumatoid arthritis: Threshold for success in RA drug development
    Stanley B Cohen
    Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, TX 75231, USA
    Nat Rev Rheumatol 8:567-8. 2012
  2. doi request reprint Small molecular therapies for rheumatoid arthritis: where do we stand?
    Stanley Cohen
    University of Texas Southwestern, Medical School, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, TX 75214, USA
    Expert Opin Investig Drugs 21:23-31. 2012
  3. doi request reprint A pilot study of rituximab in immune-mediated inner ear disease
    Stanley Cohen
    Metroplex Clinical Research Center, University of Texas Southwestern Medical School, Dallas, TX 75231, Dallas, USA
    Audiol Neurootol 16:214-21. 2011
  4. doi request reprint Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas 75235, USA
    Arthritis Rheum 58:1299-309. 2008
  5. doi request reprint Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis
    Stanley B Cohen
    Metroplex Clinical Research, Dallas, Texas 75235, USA
    Arthritis Rheum 60:335-44. 2009
  6. pmc Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas, USA
    Ann Rheum Dis 69:1158-61. 2010
  7. ncbi request reprint Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Stanley B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Arthritis Rheum 54:2793-806. 2006
  8. ncbi request reprint Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study
    Edward C Keystone
    Mount Sinai Hospital and the University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 39:2238-46. 2012
  9. ncbi request reprint Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence
    Stanley B Cohen
    The University of Texas Southwestern Medical Center, Office of Continuing Education, 5323 Harry Hines Blvd, Dallas, TX 75390 9059, USA
    J Rheumatol Suppl 81:4-30; quiz 31-4. 2008
  10. doi request reprint Targeting the B cell in rheumatoid arthritis
    Stanley B Cohen
    Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, Dallas TX 75231, USA
    Best Pract Res Clin Rheumatol 24:553-63. 2010

Detail Information

Publications15

  1. doi request reprint Rheumatoid arthritis: Threshold for success in RA drug development
    Stanley B Cohen
    Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, TX 75231, USA
    Nat Rev Rheumatol 8:567-8. 2012
    ..Such ‘go or no-go’ decision-making could be improved by a method of analysing longitudinal clinical trial data to establish a threshold for success of a new drug...
  2. doi request reprint Small molecular therapies for rheumatoid arthritis: where do we stand?
    Stanley Cohen
    University of Texas Southwestern, Medical School, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, TX 75214, USA
    Expert Opin Investig Drugs 21:23-31. 2012
    ..Development of small molecules that can be administered orally has progressed and several are under investigation as potential treatments for RA. This manuscript will update the status of the small molecules under development...
  3. doi request reprint A pilot study of rituximab in immune-mediated inner ear disease
    Stanley Cohen
    Metroplex Clinical Research Center, University of Texas Southwestern Medical School, Dallas, TX 75231, Dallas, USA
    Audiol Neurootol 16:214-21. 2011
    ..No significant adverse events were reported. The results of this study suggest further evaluation of rituximab as a treatment for IMED is indicated...
  4. doi request reprint Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas 75235, USA
    Arthritis Rheum 58:1299-309. 2008
    ..The aim of this multicenter, randomized, double-blind, placebo-controlled, phase II study was to evaluate the effects of denosumab on structural damage in patients with rheumatoid arthritis (RA) receiving methotrexate treatment...
  5. doi request reprint Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis
    Stanley B Cohen
    Metroplex Clinical Research, Dallas, Texas 75235, USA
    Arthritis Rheum 60:335-44. 2009
    ..To determine the efficacy and safety of pamapimod (a selective inhibitor of the alpha-isoform of p38 MAP kinase) as monotherapy in comparison with methotrexate (MTX) treatment in adult patients with active rheumatoid arthritis (RA)...
  6. pmc Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
    Stanley B Cohen
    Metroplex Clinical Research Center, Dallas, Texas, USA
    Ann Rheum Dis 69:1158-61. 2010
    ..Rituximab inhibited structural damage at 1 year in patients with rheumatoid arthritis (RA) who had had a previous inadequate response to tumour necrosis factor (TNF) inhibitors...
  7. ncbi request reprint Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Stanley B Cohen
    Radiant Research, Dallas, Texas 75235, USA
    Arthritis Rheum 54:2793-806. 2006
    ....
  8. ncbi request reprint Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study
    Edward C Keystone
    Mount Sinai Hospital and the University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 39:2238-46. 2012
    ....
  9. ncbi request reprint Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence
    Stanley B Cohen
    The University of Texas Southwestern Medical Center, Office of Continuing Education, 5323 Harry Hines Blvd, Dallas, TX 75390 9059, USA
    J Rheumatol Suppl 81:4-30; quiz 31-4. 2008
    ..In this program, distinguished rheumatologists weigh the evolving body of clinical evidence to draw sound conclusions and resolve key issues in managing inadequate response to treatment and in achieving optimal outcomes in RA...
  10. doi request reprint Targeting the B cell in rheumatoid arthritis
    Stanley B Cohen
    Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, Dallas TX 75231, USA
    Best Pract Res Clin Rheumatol 24:553-63. 2010
    ..Development of biomarkers that will assist our therapeutic decisions to enhance the benefit/risk ratio for our patients are needed as we move forward with further selective targeted therapies...
  11. ncbi request reprint Updates from B Cell Trials: Efficacy
    Stanley B Cohen
    University of Texas Southwestern Medical Center at Dallas, Radiant Research, Dallas, Texas 75235, USA
    J Rheumatol Suppl 77:12-7. 2006
    ..These findings support the hypothesis that B cells play an integral role in the pathogenesis of RA, and this report will review the efficacy results of clinical trials targeting B cells...
  12. ncbi request reprint Immune-mediated inner ear disease: 10-year experience
    Shelley S Broughton
    Otolaryngology, University of Texas Southwestern Medical School, Dallas, Texas, USA
    Semin Arthritis Rheum 34:544-8. 2004
    ..Limited information is available regarding clinical features of the disease, disease course, and response to treatment...
  13. ncbi request reprint An update on bisphosphonates
    Stanley B Cohen
    Radiant Research, 5939 Harry Hines Boulevard, Suite 400, Dallas, TX 75235, USA
    Curr Rheumatol Rep 6:59-65. 2004
    ..Further development of bisphosphonates as adjunctive therapy to reduce bone metastases is in progress, and trials evaluating bisphosphonates as a structure modifying agent in osteoarthritis are nearing completion...
  14. ncbi request reprint Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis
    Stanley B Cohen
    St Paul Medical Center, Dallas, Texas, USA
    J Rheumatol 30:225-31. 2003
    ....
  15. pmc A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee
    Stanley B Cohen
    Rheumatology, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Dallas, TX 75231, USA
    Arthritis Res Ther 13:R125. 2011
    ..The purpose of this two-part study was to evaluate the safety and pharmacokinetics (PK; Part A) and clinical effect (Part B) of AMG 108 in a double-blind, placebo-controlled, multiple-dose study in patients with OA of the knee...